Treatment for ADHD: is more complex treatment cost-effective for more complex cases?
E Michael Foster1, Peter S Jensen, Michael Schlander
1Department of Maternal and Child Health, The University of North Carolina, School of Public Health, 407-C Rosenau Hall, CB 7445, Chapel Hill, NC 27599, USA.
Health Services Research
|March 16, 2007
Summary
The most cost-effective treatment for attention deficit hyperactivity disorder (ADHD) depends on whether a child has comorbid conditions. Medication management is cost-effective for ADHD alone, while behavioral therapy is better for ADHD with comorbidities.
Area of Science:
- Child and Adolescent Psychiatry
- Health Economics
- Behavioral Science
Background:
- Attention Deficit Hyperactivity Disorder (ADHD) significantly impacts children's functioning.
- Effective treatment strategies are crucial for managing ADHD and its associated challenges.
- Understanding the economic value of different ADHD interventions is essential for healthcare policy.
Purpose of the Study:
- To evaluate the cost-effectiveness of three high-quality ADHD treatments compared to community care (CC).
- To investigate how the presence of comorbid disorders influences the cost-effectiveness of ADHD treatments.
- To inform policy decisions regarding ADHD intervention funding.
Main Methods:
- A randomized clinical trial involving 579 children aged 7-9.9 with ADHD.
- Participants were assigned to routine community care (CC), intensive medication management (MedMgt), behavioral treatment, or a combination.
- Cost-effectiveness was assessed from a payer perspective over 14 months, focusing on functional impairment.
Main Results:
- The optimal cost-effective ADHD treatment strategy varies based on comorbidity and willingness to pay.
- For ADHD without comorbidities, medication management (MedMgt) is consistently cost-effective.
- For ADHD with comorbidities, behavioral therapy (with or without medication) becomes more cost-effective with higher willingness to pay, anticipating future cost savings.
Conclusions:
- Treatment decisions for ADHD must account for the presence and impact of comorbid conditions.
- Cost-effectiveness analyses should be tailored to individual patient profiles, including comorbidities.
- Policy makers need to consider varying willingness to pay when allocating resources for ADHD interventions.
More Related Videos
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:26Modeling in Therapy
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in situations...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Treatment Strategies for Psychological Disorders
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...